Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities

Clinical Therapeutics

Volumn 39, Issue 7, 2017, Pages 1409-1425.e20

  Beierlein, Jennifer M ^a   McNamee, Laura M ^a   Walsh, Michael J ^a   Kaitin, Kenneth I ^b   DiMasi, Joseph A ^b   Ledley, Fred D ^a  

^a BENTLEY UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; cardiovascular therapeutics; drug development; drug discovery; innovation; quantitative modeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL PRODUCT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; BASIC RESEARCH; CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG DEVELOPMENT; GENE THERAPY; GENETIC ENGINEERING; HUMAN; MOLECULAR BIOLOGY; PRODUCT DEVELOPMENT; PUBLICATION; STEM CELL TRANSPLANTATION; TECHNOLOGY; TREATMENT INDICATION; FOOD AND DRUG ADMINISTRATION; TRANSLATIONAL RESEARCH; UNITED STATES;

CARDIOVASCULAR AGENTS; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85021240617     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.06.001     Document Type: Article

References (95)

1. Ford, E.S., Ajani, U.A., Croft, J.B., et al. Explaining the decrease in US deaths from coronary disease, 1980–2000. New England Journal of Medicine 356 (2007), 2388–2398.
2. Kantor, E.D., Rehm, C.D., Haas, J.S., et al. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 314 (2015), 1818–1830.
3. Health, United States, 2015. With Special Feature on Racial and Ethnic Health Disparities. 2016, National Center for Health Statistics http://www.cdc.gov/nchs/data/hus/hus15.pdf.
4. World Health Organization. Global status report on noncommunicable diseases, 2014.
5. Fordyce, C.B., Roe, M.T., Ahmad, T., et al. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol 65 (2015), 1567–1582.
6. Stern, C.S., Lebowitz, J., Latest drug developments in the field of cardiovascular disease. International Journal of Angiology 19 (2010), e100–e105.
7. Kinch, M.S., Surovtseva, Y., Hoyer, D., An analysis of FDA-approved drugs for cardiovascular diseases. Drug Discov Today, 2014.
8. Plump, A., Accelerating the pulse of cardiovascular R&D. Nat Rev Drug Discov 9 (2010), 823–824.
9. Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation, 2012 https://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-fda-final.pdf.
10. Gannon, F., The steps from translatable to translational research. EMBO Rep 15 (2014), 1107–1108.
11. Woodcock, J., Woosley, R., The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59 (2008), 1–12.
12. Zerhouni, E., The NIH roadmap. Science 302 (2003), 63–72.
13. Sheet, N.F., Clinical and Translational Science Awards. National Center for Research Resources (Summer, 2010), 2011.
14. Califf, R.M., Berglund, L., Linking scientific discovery and better health for the nation: The first three years of the NIH's Clinical and Translational Science Awards. Academic Medicine: Journal of the Association of American Medical Colleges, 85, 2010, 457.
15. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Food and Drug Administration, critical path report, 2004.
16. Kaitin, K.I., DiMasi, J.A., Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clinical Pharmacology & Therapeutics 89 (2011), 183–188.
17. Kaitin, K., Honig, P., Reinventing bioinnovation. Clinical Pharmacology & Therapeutics 94 (2013), 279–283.
18. Sung, N.S., Crowley, W.F. Jr, Genel, M., et al. Central challenges facing the national clinical research enterprise. JAMA 289 (2003), 1278–1287.
19. Collins, F.S., Reengineering translational science: the time is right. Science Translational Medicine, 3, 2011, 90cm17.
20. Galis, Z.S., Black, J.B., Skarlatos, S.I., National Heart, Lung, and Blood Institute and the translation of cardiovascular discoveries into therapeutic approaches. Circ Res 112 (2013), 1212–1218.
21. DiMasi, J.A., New drug development in the United States from 1963 to 1999. Clinical Pharmacology & Therapeutics 69 (2001), 286–296.
22. DiMasi, J.A., Faden, L., Factors associated with multiple FDA review cycles and approval phase times. Drug Inf J 43 (2009), 201–225.
23. DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A., Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87 (2010), 272–277.
24. Hay, M., Thomas, D.W., Craighead, J.L., et al. Clinical development success rates for investigational drugs. Nat Biotechnol 32 (2014), 40–51.
25. Rosenblatt, M., The Large Pharmaceutical Company Perspective. New England Journal of Medicine 376 (2017), 52–60.
26. Austin, D.H., (eds.) Research and development in the pharmaceutical industry, 2006, Congress of the United States, Congressional Budget Office.
27. Kaitin, K.I., Deconstructing the drug development process: the new face of innovation. Clinical Pharmacology & Therapeutics 87 (2010), 356–361.
28. Kaitin, K.I., The landscape for pharmaceutical innovation: drivers of cost-effective clinical research. Pharmaceutical Outsourcing, 2010.
29. Kaitin, K.I., DiMasi, J.A., Measuring the pace of new drug development in the user fee era. Drug Inf J 34 (2000), 673–680.
30. Berndt, E.R., Gottschalk, A.H., Philipson, T., Strobeck, M.W., Assessing the impacts of the prescription drug user fee acts (PDUFA) on the FDA approval process. AEI-Brookings Joint Center for Regulatory Studies, 2004.
31. Cohen, J.P., Sturgeon, G., Cohen, A., Measuring progress in neglected disease drug development. Clin Ther 36 (2014), 1037–1042.
32. Kaitin, K., US orphan product designations more than doubled from 2000–02 to 2006–08: Tufts Center for the Study of Drug Development Impact Report, 12, 2010, Tufts Center for the Study of Drug Development, Boston, MA, 1–5.
33. Kesselheim, A.S., Wang, B., Franklin, J.M., Darrow, J.J., Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ, 351, 2015, h4633.
34. Morris, Z.S., Wooding, S., Grant, J., The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 104 (2011), 510–520.
35. Hwang, T.J., Lauffenburger, J.C., Franklin, J.M., Kesselheim, A.S., Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012. JACC: Basic to Translational. Science 1 (2016), 301–308.
36. Eder, J., Sedrani, R., Wiesmann, C., The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 13 (2014), 577–587.
37. Cockburn, I.M., Henderson, R.M., Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. J Ind Econ 46 (1998), 157–182.
38. Toole, A.A., The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Research Policy 41 (2012), 1–12.
39. McNamee, L.M., Ledley, F.D., Patterns of technological innovation in biotech. Nat Biotechnol 30 (2012), 937–943.
40. Ledley, F., McNamee, L., Uzdil, V., Morgan, I., Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies. Gene Ther 21 (2014), 188–194.
41. Beierlein, J.M., McNamee, L.M., Walsh, M.J., Ledley, F.D., Patterns of innovation in Alzheimer's disease drug development: a strategic assessment based on technological maturity. Clin Ther 37 (2015), 1643–1651.
42. McNamee, L.M., Ledley, F.D., Modeling timelines for translational science in cancer; the impact of technological maturation. PLoS ONE, 12, 2017, e0174538.
43. McNamee, L.M., Walsh, M.J., Ledley, F.D., Timelines of translational science: From technology initiation to FDA approval. PLoS ONE, 12, 2017, e0177371.
44. Christensen, C.M., Exploring the limits of the technology S‐curve. Part I: component technologies. Production and Operations Management 1 (1992), 334–357.
45. Christensen, C.M., Exploring the limits of the technology S‐curve. Part II: Architectural technologies. Production and Operations Management 1 (1992), 358–366.
46. Foster, R., Innovation: The Attacker׳s Advantage. 1986, Summit Books, New York.
47. Antman, E.M., Clinical research and the development of medical therapeutics. Circulation Journal 78 (2014), 1267–1271.
48. Kaye, D.M., Krum, H., Drug discovery for heart failure: a new era or the end of the pipeline?. Nat Rev Drug Discov 6 (2007), 127–139.
49. Ross, J.S., Kesselheim, A.S., FDA Policy and Cardiovascular Medicine. Circulation 132 (2015), 1136–1145.
50. Junod, S.W., FDA and clinical drug trials: a short history. US Food and Drug Administration, 2014.
51. Pharmaprojects [Internet]. Citeline. https://citeline.com/products/pharmaprojects/.
52. Swinney, D., Phenotypic vs. target-based drug discovery for first-in-class medicines. Clinical Pharmacology & Therapeutics 93 (2013), 299–301.
53. Swinney, D.C., Anthony, J., How were new medicines discovered?. Nat Rev Drug Discov 10 (2011), 507–519.
54. DiMasi, J.A., Seibring, M.A., Lasagna, L., New drug development in the United States from 1963 to 1992. Clinical Pharmacology & Therapeutics 55 (1994), 609–622.
55. Pubmed Database. http://www.ncbi.nlm.nih.gov/pubmed.
56. Kinch, M.S., An overview of FDA-approved biologics medicines. Drug Discov Today 20 (2015), 393–398.
57. DiMasi, J.A., Paquette, C., The economics of follow-on drug research and development. Pharmacoeconomics 22 (2004), 1–14.
58. Bernstein, K.E., Ong, F.S., Blackwell, W.-L.B., et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65 (2013), 1–46.
59. Endo, A., A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B 86 (2010), 484–493.
60. Denninger, J.W., Marletta, M.A., Guanylate cyclase and the NO/cGMP signaling pathway. Biochimica et Biophysica Acta (BBA)-Bioenergetics 1411 (1999), 334–350.
61. DiMasi, J., The Changing Economics of New Drug Development: M&A and other Risk-Sharing Trends. 2016, Partnerships in Clinical Trials US; October 7, Boston, MA.
62. Suchy, D., Łabuzek, K., Stadnicki, A., Okopień, B., Ezetimibe–a new approach in hypercholesterolemia management. Pharmacological Reports 63 (2011), 1335–1348.
63. Lalloyer, F., Staels, B., Fibrates, glitazones, and peroxisome proliferator–activated receptors. Arterioscler Thromb Vasc Biol 30 (2010), 894–899.
64. Nayler, W.G., Dillon, J., Calcium antagonists and their mode of action: an historical overview. Br J Clin Pharmacol 21 (1986), 97S–107S.
65. Triggle, D.J., Calcium channel antagonists: clinical uses—past, present and future. Biochem Pharmacol 74 (2007), 1–9.
66. Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells. Marbán, E., (eds.) Mayo Clinic Proceedings, 2014, Elsevier.
67. Cho, G.-S., Fernandez, L., Kwon, C., Regenerative medicine for the heart: perspectives on stem-cell therapy. Antioxid Redox Signal 21 (2014), 2018–2031.
68. Madonna, R., Ferdinandy, P., De Caterina, R., et al. Recent developments in cardiovascular stem cells. Circ Res 115 (2014), e71–e78.
69. Kim, J., Shapiro, L., Flynn, A., The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. Pharmacol Ther 151 (2015), 8–15.
70. Wegener, M., Bader, A., Giri, S., How to mend a broken heart: adult and induced pluripotent stem cell therapy for heart repair and regeneration. Drug Discov Today 20 (2015), 667–685.
71. Yamakawa, H., Ieda, M., Strategies for Heart Regeneration. Int Heart J 56 (2015), 1–5.
72. Golia, E., Limongelli, G., Natale, F., et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep 16 (2014), 1–7.
73. Ridker, P.M., Lüscher, T.F., Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 35 (2014), 1782–1791.
74. Awan, Z., Genest, J., Inflammation modulation and cardiovascular disease prevention. European Journal of Preventive Cardiology 22 (2015), 719–733.
75. Schrör, K., Huber, K., Platelets, inflammation and anti-inflammatory drugs in ACS and CAD. Thromb Haemost 114 (2015), 446–448.
76. Passacquale, G., Di Giosia, P., Ferro, A., The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. Cardiovasc Res 109 (2016), 9–23.
77. Bäck, M., Hansson, G.K., Anti-inflammatory therapies for atherosclerosis. Nature Reviews Cardiology 12 (2015), 199–211.
78. DiMasi, J.A., Chakravarthy, R., Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development. Clinical Pharmacology & Therapeutics 100 (2016), 754–760.
79. Brown, D., Unfinished business: target-based drug discovery. Drug Discov Today 12 (2007), 1007–1012.
80. Christensen, C.M., The ongoing process of building a theory of disruption. Journal of Product Innovation Management 23 (2006), 39–55.
81. Christensen, C.M., Overdorf, M., Meeting the challenge of disruptive change. Harv Bus Rev 78 (2000), 66–77.
82. Christensen, C.M., Rosenbloom, R.S., Explaining the attacker׳s advantage: Technological paradigms, organizational dynamics, and the value network. Research Policy 24 (1995), 233–257.
83. Clayton, M.C., The innovator׳s dilemma: When new technologies cause great firms to fail. 1997, Harvard Business School Press, HBS Press Book, Boston, USA.
84. Meredith, J.R., Mantel Jr, Samuel, J., Appendix C Technological Forecasting. Project Management: A Managerial Approach, 9th ed, 2014, Wiley.
85. Meredith, J.R., Mantel Jr., Samuel, J., et al. Project Management: A Managerial Approach, 9th ed., 2014.
86. Carvalho, M., Fleury, A., Lopes, A.P., An overview of the literature on technology roadmapping (TRM): Contributions and trends. Technol Forecast Soc Change 80 (2013), 1418–1437.
87. Oliveira, M.G., Rozenfeld, H., Integrating technology roadmapping and portfolio management at the front-end of new product development. Technol Forecast Soc Change 77 (2010), 1339–1354.
88. Ding, M., Dong, S., Eliashberg, J., Gopalakrishnan, A., Portfolio Management in New Drug Development. 2014, Innovation and Marketing in the Pharmaceutical Industry: Springer, 83–118.
89. Cowlrick, I., Hedner, T., Wolf, R., et al. Decision‐making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information. R&D Management 41 (2011), 321–336.
90. Seidah, N.G., The proprotein convertases, 20 years later. Proprotein Convertases, 2011, 23–57.
91. Ridker, P.M., LDL cholesterol: controversies and future therapeutic directions. The Lancet 384 (2014), 607–617.
92. McNamee, L.M., Ledley, F.D., Assessing the history and value of Human Genome Sciences. Journal of Commercial Biotechnology, 19(4), 2013.
93. Aggarwal, B.B., Gupta, S.C., Kim, J.H., Historical perspectives on tumor necrosis factor and its superfamily: twenty-five years later, a golden journey. Blood, 2011 blood-2011-04-325225.
94. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 64 (2012), 4–17.
95. Cook, D., Brown, D., Alexander, R., et al. Lessons learned from the fate of AstraZeneca׳s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13 (2014), 419–431.